1. Home
  2. BSET vs SGMT Comparison

BSET vs SGMT Comparison

Compare BSET & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bassett Furniture Industries Incorporated

BSET

Bassett Furniture Industries Incorporated

N/A

Current Price

$15.35

Market Cap

153.2M

ML Signal

N/A

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$5.21

Market Cap

164.6M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BSET
SGMT
Founded
1902
2006
Country
US
US
Employees
N/A
N/A
Industry
Home Furnishings
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
153.2M
164.6M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
BSET
SGMT
Price
$15.35
$5.21
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$27.00
AVG Volume (30 Days)
15.7K
688.4K
Earning Date
05-06-2026
01-01-0001
Dividend Yield
5.35%
N/A
EPS Growth
163.06
45.49
EPS
0.70
N/A
Revenue
$456,855,000.00
$2,000,000.00
Revenue This Year
$4.51
N/A
Revenue Next Year
$3.66
N/A
P/E Ratio
$21.34
N/A
Revenue Growth
0.96
N/A
52 Week Low
$13.96
$1.73
52 Week High
$19.75
$11.41

Technical Indicators

Market Signals
Indicator
BSET
SGMT
Relative Strength Index (RSI) 36.41 40.81
Support Level $15.70 $4.92
Resistance Level $16.62 $5.29
Average True Range (ATR) 0.67 0.51
MACD -0.03 -0.06
Stochastic Oscillator 7.94 13.38

Price Performance

Historical Comparison
BSET
SGMT

About BSET Bassett Furniture Industries Incorporated

Bassett Furniture Industries Inc is a manufacturer, marketer, and retailer of home furnishings products in the United States. It operates through the following segments: The Wholesale segment focuses on the design, manufacture, sourcing, sale, and distribution of furniture products, the Retail segment which consists of company-owned stores, and the Corporate and others segment. Majority of revenue is from Wholesale sales of furniture and accessories.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: